Publications by authors named "Shi-Yu Luo"
Inositol 1, 4, 5-trisphosphate (IP3) signaling-mediated calcium release drives the contraction of vascular smooth muscles and hence regulates blood vessel volume and blood pressure. Melatonin supplementation has been suggested to be beneficial for hypertension. To determine whether the blood pressure-lowering effect of melatonin was accounted for by IP3 signaling, we evaluated the vasoconstriction response and IP3 signaling in isolated mouse thoracic aortic rings during melatonin incubation.
View Article and Find Full Text PDFMechanism of Action of Acupotomy in Inhibiting Chondrocyte Apoptosis in Rabbits with KOA through the PI3K/Akt Signaling Pathway.
Evid Based Complement Alternat Med
November 2020
Objective: We examined the effects of acupotomy on the PI3K/Akt signaling pathway to elucidate the mechanism of action of acupotomy on articular chondrocyte apoptosis among rabbits with knee osteoarthritis (KOA).
Methods: New Zealand rabbits were randomly assigned to a healthy control group, placebo group, acupotomy group, and drug group, with 10 rabbits in each group. Changes in chondrocytes were examined by hematoxylin and eosin staining, and articular chondrocyte apoptosis was measured by electron microscopy and immunofluorescence.
Molecular medicine of fragile X syndrome: based on known molecular mechanisms.
World J Pediatr
February 2016
Background: Extensive research on fragile X mental retardation gene knockout mice and mutant Drosophila models has largely expanded our knowledge on mechanism-based treatment of fragile X syndrome (FXS). In light of these findings, several clinical trials are now underway for therapeutic translation to humans.
Data Sources: Electronic literature searches were conducted using the PubMed database and ClinicalTrials.
Article Synopsis
- The overexpression of polo-like kinase 1 (Plk1) is linked to poor cancer outcomes, prompting it as a target for new anticancer drugs like volasertib, which effectively halts cancer cell growth.
- However, the effectiveness of volasertib can be compromised by the overexpression of ABCB1 (P-glycoprotein), which causes drug resistance in cancer cells.
- Combining volasertib with an ABCB1 inhibitor can enhance its anticancer effects, addressing the challenge of drug resistance in overexpressing cancer cells.
Article Synopsis
- CUDC-101 is a novel drug designed to target multiple cancer growth pathways by inhibiting EGFR, HER2, and HDAC simultaneously, showing promise in early human trials against advanced solid tumors.
- Despite its potential, there are concerns about drug resistance, particularly due to the overexpression of transport proteins ABCB1 and ABCG2, which can significantly reduce CUDC-101's effectiveness.
- Research indicates that combining CUDC-101 with agents that inhibit these transporters could enhance its effectiveness and help combat multidrug resistance in cancer treatment.
Polo-like kinase 1 (Plk1) is a serine/threonine kinase involved in the regulation of mitosis and is overexpressed in many tumor types. Inhibition of Plk1 leads to cell cycle arrest, onset of apoptosis, and cell death, thus Plk1 has emerged as an important target for cancer treatment. GSK461364 is a potent inhibitor of Plk1 that inhibits the proliferation of multiple human cancer cell lines by promoting G2/M cell cycle arrest at low concentrations.
View Article and Find Full Text PDFArticle Synopsis
- Overexpression of Polo-like kinase 1 (Plk1) is linked to various cancers, making it a key target for therapies like the selective inhibitor BI 2536, which can halt cancer cell growth at low doses.
- * Despite its potential, BI 2536 faces challenges due to acquired resistance, particularly through the overexpression of ATP-binding cassette (ABC) transporters like ABCB1 and ABCG2.
- * Combining BI 2536 with specific inhibitors or other cancer drugs that also target ABC transporters may help overcome this resistance and enhance treatment effectiveness.*